Speakers

Erik Buntinx

CEO - Managing Director, PharmaNeuroBoost

Keynote: Innovation, superiority and best practice Proof-of-Concept in CNS clinical development - 11:45 AM

Erik Buntinx, MD, CEO, founded the Belgian CNS specialty company PharmaNeuroBoost (PNB) in December 2006 and has raised up till date EUR 25 M. PNB’s platform technology is based on Buntinx’s discovery of the boosting capabilities of highly-selective serotonin 2A and dopamine 4 receptor antagonists. Buntinx is a qualified psychiatrist, and previously founded the Anima Center, an outpatient psychiatric clinic and integrated clinical research unit. He obtained his MD degree from the Catholic University of Leuven (KUL), Belgium and completed his psychiatric residency at the KUL and the University of Maastricht, The Netherlands. Finally, Buntinx achieved recently support from the FDA for a pivotal trial that uses a new endpoint demonstrating superior efficacy over standard of care in major depression: ESR (Early and Sustained Response Rate).